NRX Pharmaceuticals Files 2024 Proxy Statement
Ticker: NRXPW · Form: DEF 14A · Filed: Sep 5, 2024 · CIK: 1719406
| Field | Detail |
|---|---|
| Company | Nrx Pharmaceuticals, INC. (NRXPW) |
| Form Type | DEF 14A |
| Filed Date | Sep 5, 2024 |
| Risk Level | low |
| Pages | 16 |
| Reading Time | 20 min |
| Key Dollar Amounts | $0.001, $1.00 |
| Sentiment | neutral |
Sentiment: neutral
Topics: proxy-statement, annual-meeting, governance
TL;DR
NRX Pharma's 2024 proxy is out, vote by Oct 8!
AI Summary
NRX Pharmaceuticals, Inc. filed a DEF 14A on September 5, 2024, for its annual meeting on October 8, 2024. The company, formerly known as Big Rock Partners Acquisition Corp. until October 12, 2017, is seeking shareholder approval for matters related to its corporate governance and operations. The filing indicates no fee was required for this submission.
Why It Matters
This filing provides shareholders with crucial information regarding the company's upcoming annual meeting, allowing them to make informed decisions on corporate matters and director elections.
Risk Assessment
Risk Level: low — This is a routine DEF 14A filing for an annual meeting, not indicating immediate financial distress or significant operational changes.
Key Players & Entities
- NRX Pharmaceuticals, Inc. (company) — Registrant
- Big Rock Partners Acquisition Corp. (company) — Former company name
- 20241008 (date) — Annual meeting date
- 20240905 (date) — Filing date
FAQ
What is the purpose of this DEF 14A filing?
The purpose of this DEF 14A filing is to provide shareholders with information for the annual meeting of NRX Pharmaceuticals, Inc., scheduled for October 8, 2024.
When was NRX Pharmaceuticals, Inc. formerly known as?
NRX Pharmaceuticals, Inc. was formerly known as Big Rock Partners Acquisition Corp. until October 12, 2017.
What is the filing date of this document?
This document was filed on September 5, 2024.
Is there a fee associated with this filing?
No fee was required for this filing, as indicated by the 'No fee required' checkbox being selected.
What is the fiscal year end for NRX Pharmaceuticals, Inc.?
The fiscal year end for NRX Pharmaceuticals, Inc. is December 31.
Filing Stats: 4,929 words · 20 min read · ~16 pages · Grade level 11.4 · Accepted 2024-09-05 16:18:58
Key Financial Figures
- $0.001 — f shares of our common stock, par value $0.001 per share (" Common Stock "), to certai
- $1.00 — market on the trading day is less than $1.00 for twenty (20) trading days over a con
Filing Documents
- nrxp20240904_def14a.htm (DEF 14A) — 653KB
- card1.jpg (GRAPHIC) — 299KB
- card2.jpg (GRAPHIC) — 206KB
- logo.jpg (GRAPHIC) — 13KB
- 0001437749-24-028549.txt ( ) — 1367KB
Executive Compensation
Executive Compensation 15 Director Compensation 23
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 24 Proposal 1: Election of Class III Directors 25 Proposal 2: Share Issuance Proposal 26 Proposal 3: Reverse Split Proposal 28 Proposal 4: Ratification of Selection of Auditors 31 Certain Relationships and Related Person Transactions 33 Stockholder Proposals 34 Householding of Proxy Materials 35 Other Matters 35 NRx Pharmaceuticals, Inc. 1201 Orange Street, Suite 600 Wilmington, DE 19801 (484) 254-6134 September 5, 2024 PROXY STATEMENT This proxy statement (the " Proxy Statement "), the attached Notice of Annual Meeting of Stockholders (the " Notice ") and the enclosed proxy card are being mailed to stockholders of record on or about August 21, 2024 and are furnished in connection with the solicitation of proxies by the Board of Directors (the " Board ") of NRx Pharmaceuticals, Inc. (the " Company ," " we ," or " us ") for use at our 2024 Annual Meeting of Stockholders (the " Annual Meeting "), to be held on October 8, 2024, at 11:00 a.m., Eastern Time, in virtual-only format at https://www.cstproxy.com/nrxpharma/2024 , and at any adjournments or postponements thereof. Although not part of this Proxy Statement, we are also sending along with this Proxy Statement, our Annual Report on Form 10-K, which includes our financial statements and related notes thereto for the fiscal year ended December 31, 2023 (as amended on Form 10-K/A, the " 2023 Annual Report "). IMPORTANT NOTICE REGARDING THE AVAILABILITY OF PROXY MATERIALS FOR THE STOCKHOLDER MEETING TO BE HELD ON OCTOBER 11, 2024. This Proxy Statement and our 2023 Annual Report are available for viewing, printing and downloading at www.nrxpharma.com. Additionally, you can find a copy of our 2023 Annual Report on the website of the Securities and Exchange Commission (the " SEC " ) at https://www.sec.gov , or in the " Financial Information " section of the " Investor Relations " secti